Loading...
•
Mar 31, 2024
Arcellx Q1 2024 Earnings Report
Arcellx's financial results for Q1 2024 were reported, featuring collaboration revenue and a reduced net loss compared to the previous year.
Key Takeaways
Arcellx reported collaboration revenue of $39.3 million and a net loss of $7.2 million for the first quarter ended March 31, 2024. The company's cash, cash equivalents, and marketable securities totaled $691.0 million, expected to fund operations into 2027.
Arcellx had cash, cash equivalents, and marketable securities of $691.0 million as of March 31, 2024.
Collaboration revenue increased to $39.3 million, driven by changes in estimated transaction price with Kite Pharma, Inc.
Research and development expenses decreased slightly to $32.3 million due to reduced costs in the anito-cel clinical program.
Net loss decreased to $7.2 million, compared to $27.3 million for the same quarter in the previous year.
Arcellx
Arcellx
Arcellx Revenue by Segment
Revenue by Segment
anito-cel in rrMM Revenue
CapyFin.comACLX-002 Revenue
CapyFin.comOther R&D costs Revenue
CapyFin.comInternal costs Revenue
CapyFin.com Forward Guidance
Arcellx anticipates that its cash, cash equivalents, and marketable securities will fund its operations into 2027.
Revenue & Expenses
Visualization of income flow from segment revenue to net income